$AMRZ

Clark Stephen S purchased $249K of AMRZ

Clark Stephen S (Chief People Officer) purchased 5,260 shares of Amrize Ltd (AMRZ) at $47.31 ($0.25M total) on 2026-08-11.

Original reporting
SEC EDGAR · Clark Stephen S
Published Aug 13, 2026, 3:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 4:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AMRZ
Bullish
low confidence
Mentioned
$AMRZ
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZBullishLow
01

Why it matters

The newest fact is the specific open-market purchase size, price, and post-transaction holdings by an officer (Chief People Officer).

02

Market read

Traders may note the insider buy as a mild sentiment input, but there is no accompanying operational or financial catalyst.

03

What to watch

Insider buys are more meaningful when repeated, large relative to holdings, or accompanied by other disclosures (guidance, contracts, financing). This filing alone does not provide those corroborating signals.

Relevance 5/10Novelty 4/10Timing: filed 2026-08-13, transaction dated 2026-08-11

Background

The article is a primary-source SEC Form 4 insider transaction for Amrize Ltd (AMRZ).

Company-level read

Ticker impact

$AMRZBullishLow confidence
Context

Amrize Ltd insider Clark Stephen S bought 5,260 shares at $47.31 on 2026-08-11, totaling $248,850.60.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

Form 4 shows an officer purchase, but the filing provides no new company performance, guidance, or deal information. Insider buys can be informative, yet they are often small relative to market moves and can be driven by personal liquidity or diversification.

Market effects

No sector-wide implications disclosed; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The purchase may be routine or planned, and the article notes no pre-arranged 10b5-1 plan, which can still reflect non-informational motives.

Key entities

  • Amrize Ltd

    Company subject of the Form 4 insider transaction disclosure.

  • Clark Stephen S

    Chief People Officer who purchased 5,260 shares at $47.31.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.